Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocyte colony- stimulating factor (G-CSF) support is recommended for patients with other host-related risk factors. Methods: We evaluated the risk factors for FN-related admission in NHL patients who have received primary G-CSF (lenograstim) prophylaxis. Results: Data from 148 patients were analyzed. The incidence of neutropenic fever was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three FN-related admissions were reported. Advanced age (> 60 years), female sex, a low albumin level, and prednisone use were associated with FN-related admission in multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A comparison between diffuse large B-cell lymphoma patients treated with R-CHOP and pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal significant differences in the FN-related admission rate between the two groups, although the lenograstim-treated group had a higher incidence of severe neutropenia. Conclusions: Elderly patients, female patients, and patients with low albumin levels need to be actively followed-up for FN even when primary prophylaxis with G-CSF has been used.
Abstract
Background/Aims: Febrile neutropenia (FN) interferes with the proper chemotherapy dose density or intensity in non-Hodgkin’s lymphoma (NHL) patients. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab has an intermediate FN risk. Prophylactic granulocyte colony- stimulating factor (G-CSF) support is recommended for patients with other host-related risk factors. Methods: We evaluated the risk factors for FN-related admission in NHL patients who have received primary G-CSF (lenograstim) prophylaxis. Results: Data from 148 patients were analyzed. The incidence of neutropenic fever was 96 events (12.2%), and the median period was 3.85 days (range, 0 to 5.9); the median duration of neutropenia was 4.21 days (range, 3.3 to 5.07). Eighty-three FN-related admissions were reported. Advanced age (> 60 years), female sex, a low albumin level, and prednisone use were associated with FN-related admission in multivariable analysis (p = 0.010, p < 0.001, and p = 0.010, respectively). A comparison between diffuse large B-cell lymphoma patients treated with R-CHOP and pegylated G-CSF and those treated with R-CHOP and lenograstim did not reveal significant differences in the FN-related admission rate between the two groups, although the lenograstim-treated group had a higher incidence of severe neutropenia. Conclusions: Elderly patients, female patients, and patients with low albumin levels need to be actively followed-up for FN even when primary prophylaxis with G-CSF has been used.
참고문헌 (24)
- Dale DC, "Myelotoxicity and dose intensity of chemotherapy : reporting practices from randomized clinical trials", J Natl Compr Canc Netw, 1, pp.440~454 (2003)
- Kuderer NM, "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients", Cancer, 106, pp.2258~2266 (2006)
- Lyman GH, "Risk of mortality in patients with cancer who experience febrile neutropenia", Cancer, 116, pp.5555~5563 (2010)
- Kwak LW, "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma : results of a tree-structured survival analysis", J Clin Oncol, 8, pp.963~977 (1990)
- Lyman GH, "Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma : a nationwide study", J Clin Oncol, 22, pp.4302~4311 (2004)
- Yamaguchi H, "Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma", J Clin Exp Hematop, 51, pp.1~5 (2011)
- Aapro MS, "2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours", Eur J Cancer, 47, pp.8~32 (2011)
- Smith TJ, "Recommendations for the use of WBC growth factors : American Society of Clinical Oncology Clinical Practice Guideline Update", J Clin Oncol, 33, pp.3199~3212 (2015)
- Lyman GH, "Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma", Cancer, 98, pp.2402~2409 (2003)
- Lyman GH, "Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy : a systematic review", Crit Rev Oncol Hematol, 90, pp.190~199 (2014)
- "Hematopoietic growth factors (version 1.0, 2020)" (2020)[URL]
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Hryniuk W, "The importance of dose intensity in chemotherapy of metastatic breast cancer", J Clin Oncol, 2, pp.1281~1288 (1984)
- Crawford J, "Hematopoietic growth factors : ESMO clinical practice guidelines for the applications", Ann Oncol, 21(Suppl 5), pp.v248~v251 (2010)
- Lyman GH, "Epidemiology of febrile neutropenia", Support Cancer Ther, 1, pp.23~35 (2003)
- Osby E, "CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment : results of a Nordic Lymphoma Group randomized trial", Blood, 101, pp.3840~3848 (2003)
- Kuderer NM, "Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy : a systematic review", J Clin Oncol, 25, pp.3158~3167 (2007)
- Talcott JA, "Risk assessment in cancer patients with fever and neutropenia : a prospective, two-center validation of a prediction rule", J Clin Oncol, 10, pp.316~322 (1992)
- Salar A, "The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21 : findings from clinical practice", Leuk Res, 36, pp.548~553 (2012)
- Pettengell R, "Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma : data from the INC-EU Prospective Observational European Neutropenia Study", Br J Haematol, 144, pp.677~685 (2009)
- Laskey RA, "Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer", Gynecol Oncol, 125, pp.625~630 (2012)
- Intragumtornchai T, "A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma", Leuk Lymphoma, 37, pp.351~360 (2000)
- Bozzoli V, "Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma", Br J Haematol, 169, pp.787~794 (2015)
- Kubo K, "A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R)chemotherapy for malignant lymphoma", Br J Haematol, 174, pp.563~570 (2016)